SRT2183 impairs ovarian cancer by facilitating autophagy

The 5-year survival rate of ovarian cancer patients is only 47%, and developing novel drugs for ovarian cancer is needed. Herein, we evaluated if and how SRT2183, a sirtuin-1 activator, impairs the ovarian cancer cells. OVCAR-3 and A2780 cells were treated with SRT2183. Cell viability was measured b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Tingting, Hu, Yanfen, He, Weipeng, Shang, Yuru, Yang, Xiaohong, Gong, Liyun, Zhang, Xianbin, Gong, Peng, Yang, Guofen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762476/
https://www.ncbi.nlm.nih.gov/pubmed/33223507
http://dx.doi.org/10.18632/aging.104126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762476/
https://www.ncbi.nlm.nih.gov/pubmed/33223507
http://dx.doi.org/10.18632/aging.104126

Ejemplares similares